HPTN 077
![HPTN 077 logo where the 0 in 077 is a circular life preserver](/sites/default/files/styles/max_width_012000_480/public/images/8c/hptn-077-1024x972_0.jpg?f=5c74178b&itok=9lBgrXwM)
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
OBJECTIVE
This study evaluated the safety, tolerability, and pharmacokinetics (which is how the body interacts with drugs) of an investigational, injectable HIV medicine (GSK1265744) in healthy, HIV-uninfected adults.
STUDY TYPE: HIV Prevention
DURATION: February 2015 - July 2018
PHASE: IIA
STUDY DESIGN: Randomized, parallel assigned, quadrupal masked interventional study
POPULATION: Healthy volunteers aged 18 - 65 years old
NUMBER OF SITES: 8
SITE LOCATIONS: US, Brazil, Malawi, and South Africa
STATUS: Complete
RESULTS
![Mathead for journal acticle titled, "Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial"](/sites/default/files/styles/landscape_3x2_032000_1280x853/public/images/3f/results-hptn077-20181105_0.png?f=66c1f3d2&itok=Ad31UCyb)
![Masthead for a research article titled, "Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial."](/sites/default/files/styles/landscape_3x2_012000_480x320/public/images/3f/results-hptn077-20181105.png?f=fc12fcdf&itok=l3pXYkul)
![A masthead for a journal article titled, "A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP."](/sites/default/files/styles/landscape_3x2_012000_480x320/public/images/8b/results-hptn077-20220810.png?f=08dbfa19&itok=tDS-z471)
![A masthead for journal article titled, "Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077"](/sites/default/files/styles/landscape_3x2_032000_1280x853/public/images/9c/results-hptn077-20200901.png?f=a09bab8f&itok=YHhw2Lvf)
![A masthead for a journal article titled, "Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial"](/sites/default/files/styles/landscape_3x2_032000_1280x853/public/images/c0/results-hptn077-20200707.png?f=438b0ab6&itok=JSMnaleH)